Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 5/20 | 0.40 |
| ▸ | TYR | P14679 | 5/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14831326 | 0.98 | CYP1A2 (0.43) | CYP1A2CPB2ALPIPKMPTGS1 | |
| SCHEMBL4727798 | 0.88 | CYP1A2 (0.45) | CYP1A2CPB2ALPIPKMPTGS1 | |
| SCHEMBL4726518 | 0.88 | CYP1A2 (0.45) | CYP1A2CPB2ALPIPKMPTGS1 | |
| SCHEMBL4437439 | 0.87 | SLC7A5 (0.44) | CYP1A2CPB2ALPIPKMPTGS1 | |
| SCHEMBL7001068 | 0.87 | SLC7A5 (0.44) | CYP1A2CPB2ALPIPKMPTGS1 | |
| SCHEMBL503556 | 0.83 | CYP1A2 (0.44) | CYP1A2CPB2ALPIPKMPTGS1 | |
| SCHEMBL27974517 | 0.83 | CYP1A2 (0.46) | CYP1A2CPB2ALPIPKMPTGS1 | |
| SCHEMBL3808000 | 0.83 | CPB2 (0.42) | CYP1A2CPB2SLC1A3CPB1GRIA1 | |
| SCHEMBL18074129 | 0.83 | CPB2 (0.42) | CYP1A2CPB2SLC1A3CPB1GRIA1 | |
| SCHEMBL3003975 | 0.83 | CPB2 (0.41) | CYP1A2CPB2ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025048497-A1 | NOVEL HISTIDINE AMIDE CHOLESTEROL COMPOUND, AND RNA DELIVERY LIPID NANOPARTICLES COMPRISING SAME | 충남대학교산학협력단 | 2025-03-06 | — | — | WO | claimed |
| WO-2025043394-A1 | KIT FOR FORMING SUPRAMOLECULAR SELF-ASSEMBLY COMPLEX AND USE THEREOF | 北京睿创康泰医药研究院有限公司 | 2025-03-06 | — | — | WO | claimed |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | TREVENA, INC. | 2024-01-25 | — | — | US | claimed |
| WO-2021216529-A1 | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2021-10-28 | — | — | WO | claimed |
| US-20210324005-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | TREVENA, INC. | 2021-10-21 | — | — | US | claimed |
| US-20180010211-A1 | ZIRCONIUM EXTRACTANT AND METHOD FOR EXTRACTING ZIRCONIUM | SUMITOMO METAL MINING CO., LTD. (JP) | 2018-01-11 | — | — | US | claimed |
| CN-104583427-B | Indium extracting agent and indium extracting method | 国立大学法人九州大学 | 2016-09-21 | — | — | CN | claimed |
| CN-104822851-B | Nickel extraction method | 国立大学法人九州大学 | 2016-09-21 | — | — | CN | claimed |
| CN-105074023-B | noble metal and rhenium extracting agent, and method for extracting noble metal and rhenium using same | 国立大学法人九州大学 | 2016-09-14 | — | — | CN | claimed |
| CN-104540972-B | Valuable metal separation method | 国立大学法人九州大学 | 2016-08-24 | — | — | CN | claimed |
| WO-2010077339-A2 | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| EP-2023730-A1 | BETULIN DERIVED COMPOUNDS AS ANTI-FEEDANTS FOR PLANT PESTS | Valtion Teknillinen Tutkimuskeskus (FI) | 2009-02-18 | — | — | EP | claimed |
| WO-2007141383-A9 | BETULIN DERIVED COMPOUNDS AS ANTI-FEEDANTS FOR PLANT PESTS | VALTION TEKNILLINEN (FI) | 2008-07-17 | — | — | WO | claimed |
| WO-2007141383-A1 | BETULIN DERIVED COMPOUNDS AS ANTI-FEEDANTS FOR PLANT PESTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | claimed |
| US-6949658-B2 | Process for producing optically active α-amino acid and optically active α-amino acid amide | MITSUBISHI RAYON CO., LTD. (JP) | 2005-09-27 | — | — | US | claimed |
| US-5486595-A | Tumor necrosis factor inhibitors | CENTECOR, INC. (US) | 1996-01-23 | — | — | US | claimed |
| WO-1995026744-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CENTOCOR, INC. (US) | 1995-10-12 | — | — | WO | claimed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| EP-0371543-A2 | Gastrin releasing peptide antagonists | MERCK & CO. INC. (US) | 1990-06-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210324005-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | ARRB1, ADRB1, FGB | CYP1A2 4688/4885CPB2 686/4885ALPI 4805/4885 |
| US-20180010211-A1 | ZIRCONIUM EXTRACTANT AND METHOD FOR EXTRACTING ZIRCONIUM | ZKSCAN2, ZRANB2, PEF1 | CYP1A2 4465/4885CPB2 1699/4885ALPI 1559/4885 |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | ARRB1, FGB, SARS1 | CYP1A2 4703/4885CPB2 625/4885ALPI 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.